IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunity

Upasana Sahu (), Matthew P. Mullarkey, Sara A. Murphy, Joshua C. Anderson, Vasanta Putluri, Abu Hena Mostafa Kamal, Jun Hyoung Park, Tae Jin Lee, Alexander L. Ling, Benny A. Kaipparettu, Ashok Sharma, Nagireddy Putluri, Pamela L. Wenzel, Christopher D. Willey, E. Antonio Chiocca, James M. Markert and Balveen Kaur ()
Additional contact information
Upasana Sahu: Medical College of Georgia at Augusta University
Matthew P. Mullarkey: The University of Texas Health Science Center at Houston
Sara A. Murphy: Medical College of Georgia at Augusta University
Joshua C. Anderson: University of Alabama at Birmingham
Vasanta Putluri: Baylor College of Medicine
Abu Hena Mostafa Kamal: Baylor College of Medicine
Jun Hyoung Park: Baylor College of Medicine
Tae Jin Lee: Medical College of Georgia at Augusta University
Alexander L. Ling: Brigham and Women’s Hospital
Benny A. Kaipparettu: Baylor College of Medicine
Ashok Sharma: Medical College of Georgia at Augusta University
Nagireddy Putluri: Baylor College of Medicine
Pamela L. Wenzel: The University of Texas Health Science Center at Houston
Christopher D. Willey: University of Alabama at Birmingham
E. Antonio Chiocca: Brigham and Women’s Hospital
James M. Markert: The University of Alabama at Birmingham
Balveen Kaur: Medical College of Georgia at Augusta University

Nature Communications, 2025, vol. 16, issue 1, 1-21

Abstract: Abstract Identification of isocitrate dehydrogenase (IDH) mutations has uncovered the crucial role of metabolism in gliomagenesis. Oncolytic herpes virus (oHSV) initiates direct tumor debulking by tumor lysis and activates anti-tumor immunity, however, little is known about the role of glioma metabolism in determining oHSV efficacy. Here we identify that oHSV rewires central carbon metabolism increasing glucose utilization towards oxidative phosphorylation and shuttling glutamine towards reductive carboxylation in IDH wildtype glioma. The switch in metabolism results in increased lipid synthesis and cellular ROS. PKC induces ACSL4 in oHSV treated cells leading to lipid peroxidation and ferroptosis. Ferroptosis is critical to launch an anti-tumor immune response which is important for viral efficacy. Mutant IDH (IDHR132H) gliomas are incapable of reductive carboxylation and hence ferroptosis. Pharmacological blockade of IDHR132H induces ferroptosis and anti-tumor immunity. This study provides a rationale to use an IDHR132H inhibitor to treat high grade IDH-mutant glioma patients undergoing oHSV treatment.

Date: 2025
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-58911-2 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58911-2

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-58911-2

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().